December 2014. Volume 10. Number 4

Association between prenatal exposure to antiretroviral therapy and birth defects. Can we be reassured?

 
 
 
 
 
 
 
 
 
 
Rating: 0 (0 Votes)
Newsletter Free Subscription
Regularly recieve most recent articles by e-mail
Subscribe
Print
Add to library
Discuss this article

AVC | Critically appraised articles

Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med. 2014;11:e1001635.
Reviewers: Jullien S1, Orejón de Luna G2.
1Servicio de Pediatría. Hospital Universitario de Girona Dr. Josep Trueta. Girona. España.
2CS General Ricardos. Madrid. España.
Correspondence: Sophie Jullien. Email: sophjullien@gmail.com
Reception date: 03/09/2014
Acceptance date: 11/09/2014
Publication date: 15/10/2014

Abstract

Authors' conclusions: a specific association is found between in utero exposure to zidovudine and heart defects. The association between efavirenz and neurological defects must be interpreted with caution. For the other drugs not associated with birth defects, the results were reassuring. The impact that antiretroviral drugs might have on the apparition of congenital defects has to be overcome by the main treatment goal, to avoid HIV transmission.

Reviewers' commentary: in utero exposure to zidovudine has been associated with the occurrence of cardiac defects in the newborn. It also described the relationship of efavirenz with neurological defects, but results have been inconclusive. No birth defects were found associated with other antiretrovirals. However, we must continue to monitor the occurrence of adverse effects and further studies are needed to assess the safety of such treatment

How to cite this article

Jullien S, Orejón de Luna G. Asociación entre exposición prenatal a antirretrovirales y defectos congénitos. ¿Podemos estar tranquilos? Evid Pedatr. 2014;10:67.

AVC | Critically appraised articles

Sibiude J, Mandelbrot L, Blanche S, Le Chenadec J, Boullag-Bonnet N, Faye A et al. Association between prenatal exposure to antiretroviral therapy and birth defects: an analysis of the French perinatal cohort study (ANRS CO1/CO11). PLoS Med. 2014;11:e1001635.
Reviewers: Jullien S1, Orejón de Luna G2.
1Servicio de Pediatría. Hospital Universitario de Girona Dr. Josep Trueta. Girona. España.
2CS General Ricardos. Madrid. España.
Correspondence: Sophie Jullien. Email: sophjullien@gmail.com
Reception date: 03/09/2014
Acceptance date: 11/09/2014
Publication date: 15/10/2014

How to cite this article

Jullien S, Orejón de Luna G. Asociación entre exposición prenatal a antirretrovirales y defectos congénitos. ¿Podemos estar tranquilos? Evid Pedatr. 2014;10:67.

References

  1. Shapiro RL, Hughes MD, Ogwu A, Kitch D, Lockman S, Moffat C, et al. Antiretroviral regimens in pregnancy and breast-feeding in Botswana. N Engl J Med. 2010;362:2282-94.
  2. Bussmann H, Wester CW, Wester CN, Lekoko B, Okezie O, Thomas AM, et al. Pregnancy rates and birth outcomes among women on efavirenz-containing highly active antiretroviral therapy in Botswana. J Acquir Immune Defic Syndr. 2007;45:269-73.
  3. Watts DH, Huang S, Culnane M, Kaiser KA, Scheuerle A, Mofenson L, et al. Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. J Perinat Med. 2011;39:163-70.
  4. Nielsen-Saines K, Komarow L, Cu-Uvin S, Jourdain G, Klingman KL, Shapiro DE, et al. Infant outcomes after maternal antiretroviral exposure in resource-limited settings. Pediatrics. 2012;129:e1525-32.
  5. Gibb DM, Kizito H, Russell EC, Chidziva E, Zalwango E, Nalumenya R, et al. Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial. PLoS Med. 2012;9:e1001217.
  6. Thorne C, Newell ML. Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? Drug Saf. 2007;30:203-13.
15/10/2014

Linked Comment